C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps
Patients with severe COVID-19 develop acute respiratory distress syndrome (ARDS) that may progress to cytokine storm syndrome, organ dysfunction, and death. Considering that complement component 5a (C5a), through its cellular receptor C5aR1, has potent proinflammatory actions and plays immunopathological roles in inflammatory diseases, we investigated whether the C5a/C5aR1 pathway could be involved in COVID-19 pathophysiology. C5a/C5aR1 signaling increased locally in the lung, especially in neutrophils of critically ill patients with COVID-19 compared with patients with influenza infection, as well as in the lung tissue of K18-hACE2 Tg mice (Tg mice) infected with SARS-CoV-2. Genetic and pharmacological inhibition of C5aR1 signaling ameliorated lung immunopathology in Tg-infected mice. Mechanistically, we found that C5aR1 signaling drives neutrophil extracellular traps-dependent (NETs-dependent) immunopathology. These data confirm the immunopathological role of C5a/C5aR1 signaling in COVID-19 and indicate that antagonists of C5aR1 could be useful for COVID-19 treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:133 |
|---|---|
| Enthalten in: |
The Journal of clinical investigation - 133(2023), 12 vom: 15. Juni |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
80295-54-1 |
|---|
| Anmerkungen: |
Date Completed 16.06.2023 Date Revised 18.06.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1172/JCI163105 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356076296 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356076296 | ||
| 003 | DE-627 | ||
| 005 | 20231226065705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/JCI163105 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356076296 | ||
| 035 | |a (NLM)37104043 | ||
| 035 | |a (PII)e163105 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Silva, Bruna M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.06.2023 | ||
| 500 | |a Date Revised 18.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Patients with severe COVID-19 develop acute respiratory distress syndrome (ARDS) that may progress to cytokine storm syndrome, organ dysfunction, and death. Considering that complement component 5a (C5a), through its cellular receptor C5aR1, has potent proinflammatory actions and plays immunopathological roles in inflammatory diseases, we investigated whether the C5a/C5aR1 pathway could be involved in COVID-19 pathophysiology. C5a/C5aR1 signaling increased locally in the lung, especially in neutrophils of critically ill patients with COVID-19 compared with patients with influenza infection, as well as in the lung tissue of K18-hACE2 Tg mice (Tg mice) infected with SARS-CoV-2. Genetic and pharmacological inhibition of C5aR1 signaling ameliorated lung immunopathology in Tg-infected mice. Mechanistically, we found that C5aR1 signaling drives neutrophil extracellular traps-dependent (NETs-dependent) immunopathology. These data confirm the immunopathological role of C5a/C5aR1 signaling in COVID-19 and indicate that antagonists of C5aR1 could be useful for COVID-19 treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Complement | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Innate immunity | |
| 650 | 4 | |a Molecular pathology | |
| 650 | 7 | |a Complement C5a |2 NLM | |
| 650 | 7 | |a 80295-54-1 |2 NLM | |
| 700 | 1 | |a Gomes, Giovanni F |e verfasserin |4 aut | |
| 700 | 1 | |a Veras, Flavio P |e verfasserin |4 aut | |
| 700 | 1 | |a Cambier, Seppe |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Gabriel Vl |e verfasserin |4 aut | |
| 700 | 1 | |a Quadros, Andreza U |e verfasserin |4 aut | |
| 700 | 1 | |a Caetité, Diego B |e verfasserin |4 aut | |
| 700 | 1 | |a Nascimento, Daniele C |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Camilla M |e verfasserin |4 aut | |
| 700 | 1 | |a Silva, Juliana C |e verfasserin |4 aut | |
| 700 | 1 | |a Damasceno, Samara |e verfasserin |4 aut | |
| 700 | 1 | |a Schneider, Ayda H |e verfasserin |4 aut | |
| 700 | 1 | |a Beretta, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Batah, Sabrina S |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Icaro Ms |e verfasserin |4 aut | |
| 700 | 1 | |a Paiva, Isadora M |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a Salina, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Martins, Ronaldo |e verfasserin |4 aut | |
| 700 | 1 | |a Cebinelli, Guilherme Cm |e verfasserin |4 aut | |
| 700 | 1 | |a Bibo, Naira L |e verfasserin |4 aut | |
| 700 | 1 | |a Jorge, Daniel M |e verfasserin |4 aut | |
| 700 | 1 | |a Nakaya, Helder I |e verfasserin |4 aut | |
| 700 | 1 | |a Zamboni, Dario S |e verfasserin |4 aut | |
| 700 | 1 | |a Leiria, Luiz O |e verfasserin |4 aut | |
| 700 | 1 | |a Fabro, Alexandre T |e verfasserin |4 aut | |
| 700 | 1 | |a Alves-Filho, José C |e verfasserin |4 aut | |
| 700 | 1 | |a Arruda, Eurico |e verfasserin |4 aut | |
| 700 | 1 | |a Louzada-Junior, Paulo |e verfasserin |4 aut | |
| 700 | 1 | |a Oliveira, Renê D |e verfasserin |4 aut | |
| 700 | 1 | |a Cunha, Larissa D |e verfasserin |4 aut | |
| 700 | 1 | |a Van Mol, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Vanderbeke, Lore |e verfasserin |4 aut | |
| 700 | 1 | |a Feys, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Wauters, Els |e verfasserin |4 aut | |
| 700 | 1 | |a Brandolini, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Aramini, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Cunha, Fernando Q |e verfasserin |4 aut | |
| 700 | 1 | |a Köhl, Jörg |e verfasserin |4 aut | |
| 700 | 1 | |a Allegretti, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Lambrechts, Diether |e verfasserin |4 aut | |
| 700 | 1 | |a Wauters, Joost |e verfasserin |4 aut | |
| 700 | 1 | |a Proost, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Cunha, Thiago M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 133(2023), 12 vom: 15. Juni |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
| 773 | 1 | 8 | |g volume:133 |g year:2023 |g number:12 |g day:15 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI163105 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 133 |j 2023 |e 12 |b 15 |c 06 | ||